English court resumes Amgen cholesterol patent suit

The English High Court has lifted a stay on Amgen’s lawsuit which accused Sanofi-Aventis and Regeneron of infringing a patent covering pharmaceuticals which treat elevated cholesterol levels.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Medtech

Haier division scores win in global patent dispute

10 December 2020 Flexicare infringed a breathing tube patent owned by New Zealand appliance maker Fisher & Paykel (F&P), the English High Court has ruled.

Biotechnology

Regeneron sued over antibody protein used to treat Trump’s COVID-19 symptoms

6 October 2020 Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.

Americas

Amgen urges Fed Circuit to deny Sandoz petition

27 August 2020 Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

English court resumes Amgen cholesterol patent suit

More on this story

Editor's picks

Editor's picks

More features